全文获取类型
收费全文 | 333篇 |
免费 | 41篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 6篇 |
妇产科学 | 8篇 |
基础医学 | 89篇 |
口腔科学 | 1篇 |
临床医学 | 31篇 |
内科学 | 49篇 |
神经病学 | 12篇 |
特种医学 | 11篇 |
外科学 | 14篇 |
综合类 | 6篇 |
预防医学 | 17篇 |
药学 | 6篇 |
肿瘤学 | 119篇 |
出版年
2021年 | 2篇 |
2016年 | 2篇 |
2014年 | 2篇 |
2013年 | 8篇 |
2012年 | 15篇 |
2011年 | 16篇 |
2010年 | 6篇 |
2009年 | 6篇 |
2008年 | 16篇 |
2007年 | 12篇 |
2006年 | 22篇 |
2005年 | 14篇 |
2004年 | 19篇 |
2003年 | 15篇 |
2002年 | 14篇 |
2001年 | 11篇 |
2000年 | 19篇 |
1999年 | 19篇 |
1998年 | 13篇 |
1997年 | 7篇 |
1996年 | 7篇 |
1995年 | 12篇 |
1994年 | 15篇 |
1993年 | 5篇 |
1992年 | 11篇 |
1991年 | 12篇 |
1990年 | 9篇 |
1989年 | 5篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1985年 | 4篇 |
1984年 | 8篇 |
1983年 | 4篇 |
1980年 | 2篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1968年 | 2篇 |
1943年 | 1篇 |
1938年 | 1篇 |
1936年 | 1篇 |
1935年 | 2篇 |
1934年 | 1篇 |
1933年 | 1篇 |
1931年 | 1篇 |
1930年 | 2篇 |
1928年 | 2篇 |
1927年 | 1篇 |
1921年 | 3篇 |
排序方式: 共有374条查询结果,搜索用时 125 毫秒
1.
Irina V. Tereschenko Victoria M. Basham Bruce A.J. Ponder Paul D.P. Pharoah 《Human mutation》2002,19(2):184-184
We have screened index cases from 25 Russian breast/ovarian cancer families for germ‐line mutations in all coding exons of the BRCA1 and BRCA2 genes, using multiplex heteroduplex analysis. In addition we tested 22 patients with breast cancer diagnosed before age 40 without family history and 6 patients with bilateral breast cancer. The frequency of families with germline mutations in BRCA was 16% (4/25). One BRCA1 mutation, 5382insC, was found in three families. The results of present study, and those of a separate study of 19 breast‐ovarian cancer families, suggest that BRCA1 5382insC is a founder mutation in the Russian population. Three BRCA2 mutations were found in patients with breast cancer without family history: two in young patients and one in patients with bilateral breast cancer. Four novel BRCA2 mutations were identified: three frameshift (695insT, 1528del4, 9318del4) and one nonsense (S1099X). © 2002 Wiley‐Liss, Inc. 相似文献
2.
Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy? 总被引:5,自引:1,他引:5 下载免费PDF全文
C Eng V Murday S Seal S Mohammed S V Hodgson M A Chaudary I S Fentiman B A Ponder R A Eeles 《Journal of medical genetics》1994,31(6):458-461
Cowden syndrome is an autosomal dominant condition of multiple hamartomas. Patients with this phakomatosis have an increased risk of breast cancer and thyroid tumours. Lhermitte-Duclos disease is usually a sporadic condition of cerebellar ganglion cell hypertrophy, ataxia, mental retardation, and self-limited seizure disorder. We describe a three generation family with Cowden syndrome and Lhermitte-Duclos disease. Karyotyping performed on the peripheral lymphocytes of the proband and her affected mother showed a 46,XX complement. Single strand conformational polymorphism analysis failed to show any germline p53 mutations as a cause of the syndrome in this family. 相似文献
3.
N J Froggatt J Koch R Davies D G Evans A Clamp O W Quarrell J Weissenbach S V Hodgson B A Ponder D E Barton et al. 《Journal of medical genetics》1995,32(5):352-357
Hereditary Non-polyposis Colon Cancer Syndrome (HNPCC) is the most common cause of familial colorectal cancer. Molecular genetic studies of HNPCC have shown evidence of locus heterogeneity, and mutations in four genes (hMSH2, hMLH1, hPMS1, and hPMS2) which encode components of the mismatch enzyme repair system may cause HNPCC. To determine the extent and nature of locus heterogeneity in HNPCC, we performed genetic linkage studies in 14 HNPCC families from eastern and north-western England. Linkage to hMLH1 was excluded in six families, each of which were likely to be linked to hMSH2 (lod score > 1.0 in each family and total lod score for all six families = 7.64). Linkage to hMSH2 was excluded in three families, each of which were likely to be linked to hMLH1 (lod score > 1.0 in each family and total lod score at hMLH1 for all three families = 3.93). In the remaining five families linkage to hMSH2 or hMLH1 could not be excluded. These results confirm locus heterogeneity in HNPCC and suggest that, in the population studied, most large families with HNPCC will have mutations in hMSH2 or hMLH1. We did not detect any correlation between clinical phenotype and the genetic linkage results, but a Muir-Torre syndrome family excluded from linkage to hMLH1 was likely to be linked to hMSH2 and showed microsatellite instability in a tumour from an affected relative. 相似文献
4.
5.
Bettina Kuschel Georgia Chenevix-Trench Amanda B Spurdle Xiaoqing Chen John L Hopper Graham G Giles Margret McCredie Jenny Chang-Claude Catherine S Gregory Nick E Day Douglas F Easton Bruce A J Ponder Alison M Dunning Paul D P Pharoah 《Cancer epidemiology, biomarkers & prevention》2005,14(7):1828-1831
A substantial proportion of the familial risk of breast cancer may be due to genetic variants, each contributing a small effect. The protein encoded by ERCC2 is a key enzyme involved in nucleotide excision repair, in which gene defects could lead to cancer prone syndromes such as Xeroderma pigmentosum D. We have examined the association between single nucleotide polymorphisms in the ERCC2 gene and the incidence of invasive breast cancer in three case-control series, with a maximum of 3,634 patients and of 3,340 controls. None of the three single nucleotide polymorphisms were significantly associated with the incidence of breast cancer. 相似文献
6.
Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes 总被引:3,自引:1,他引:3
Hepatic gene therapy could be used to treat a number of inherited blood diseases such as hemophilia or thrombophilia. Although liver-directed retroviral transduction can result in long-term gene expression in vivo, the low level of protein production has limited its clinical application. We reasoned that the insertion of liver-specific promoters into retroviral vectors would increase gene expression in vivo. The 347- bp human alpha 1-antitrypsin (hAAT), the 810-bp murine albumin (mAIb), the 490-bp rat phosphoenolpyruvate carboxykinase (rPECK), and the 596- bp rat liver fatty acid binding protein promoters were inserted into a Moloney murine leukemia retroviral backbone containing the hAAT reporter gene. Vectors that produced appropriately sized RNA and hAAT protein in vitro were tested in vivo by transducing regenerating rat livers. Long-term serum expression of the hAAT reporter gene was normalized to retroviral transduction efficiency as determined by using a polymerase chain reaction-based assay of genomic DNA from transduced rat livers. The hAAT, mAIb, and rPEPCK promoters were, respectively, 35- , 8-, and 0.02-fold as strong as the previously studied constitutive Pol-II promoter. We conclude that the hAAT promoter resulted in the highest expression from a retroviral vector and may result in therapeutically significant expression of other clinically significant blood proteins. 相似文献
7.
Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs 下载免费PDF全文
The effect of neonatal gene transfer on antibody formation was determined using a retroviral vector (RV) expressing human factor IX (hFIX). Normal mice from different strains injected intravenously with RV as newborns achieved therapeutic levels of hFIX without antibody production and were tolerant as adults to challenge with hFIX. Neonatal hemophilia B mice that received different amounts of RV achieved stable and dose-related expression of hFIX without anti-hFIX antibody formation. After protein challenge, antibody formation was markedly reduced for animals that expressed hFIX at levels higher than 14 ng/mL (0.3% of normal). However, antibodies developed for animals that received the lowest dose of RV and expressed hFIX at approximately 2 ng/mL before protein challenge. In dogs, neonatal injection of a high dose of RV resulted in 500 ng/mL hFIX in plasma without antibody formation. We conclude that neonatal gene transfer with RV does not induce antibody responses to hFIX in mice or dogs and that mice achieving levels greater than 3 x 10-10 M hFIX are usually tolerant to protein injection as adults. Low-dose gene therapy or frequent protein injections in the neonatal period might induce tolerance to subsequent injections of protein with a low risk for adverse effects. 相似文献
8.
9.
10.
Effects of Neonatal Enzyme Replacement Therapy and Simvastatin Treatment on Cervical Spine Disease in Mucopolysaccharidosis I Dogs 下载免费PDF全文
Joseph A Chiaro Patricia O'Donnell Eileen M Shore Neil R Malhotra Katherine P Ponder Mark E Haskins Lachlan J Smith 《Journal of bone and mineral research》2014,29(12):2610-2617
Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease characterized by deficient α‐L‐iduronidase activity, leading to the accumulation of poorly degraded glycosaminoglycans (GAGs). Children with MPS I exhibit high incidence of spine disease, including accelerated disc degeneration and vertebral dysplasia, which in turn lead to spinal cord compression and kyphoscoliosis. In this study we investigated the efficacy of neonatal enzyme replacement therapy (ERT), alone or in combination with oral simvastatin (ERT + SIM) for attenuating cervical spine disease progression in MPS I, using a canine model. Four groups were studied: normal controls; MPS I untreated; MPS I ERT‐treated; and MPS I ERT + SIM–treated. Animals were euthanized at age 1 year. Intervertebral disc condition and spinal cord compression were evaluated from magnetic resonance imaging (MRI) images and plain radiographs, vertebral bone condition and odontoid hypoplasia were evaluated using micro–computed tomography (µCT), and epiphyseal cartilage to bone conversion was evaluated histologically. Untreated MPS I animals exhibited more advanced disc degeneration and more severe spinal cord compression than normal animals. Both treatment groups resulted in partial preservation of disc condition and cord compression, with ERT + SIM not significantly better than ERT alone. Untreated MPS I animals had significantly lower vertebral trabecular bone volume and mineral density, whereas ERT treatment resulted in partial preservation of these properties. ERT + SIM treatment demonstrated similar, but not greater, efficacy. Both treatment groups partially normalized endochondral ossification in the vertebral epiphyses (as indicated by absence of persistent growth plate cartilage), and odontoid process size and morphology. These results indicate that ERT begun from a very early age attenuates the severity of cervical spine disease in MPS I, particularly for the vertebral bone and odontoid process, and that additional treatment with simvastatin does not provide a significant additional benefit over ERT alone. © 2014 American Society for Bone and Mineral Research. 相似文献